The 18-week open-label Phase 3 study evaluated up to three TrenibotE treatments in glabellar lines, demonstrating no neutralizing antibody development, consistent safety across sequences and rapid severity reduction noted within eight hours of administration. TrenibotE is a first-in-class botulinum neurotoxin serotype E with rapid onset at the earliest eight-hour assessment and a 2–3 week duration, offering a differentiated profile from existing products pending approval. A survey of aesthetics clinics treating GLP-1 agonist patients revealed that 52% express facial concerns during weight-loss therapy, 32% are new to aesthetic services, and 82% and 58% cite cost and fear of unnatural outcomes as barriers, respectively.